FAST-A Study to evaluate the Efficacy and Safety of Quetiapin IR in Patients with acute Psychosis - FAST
Study identifier:D1443L00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
-
Medical condition
Psychotic Disorders
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine
Sex
All
Actual Enrollment
-
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 May 2007
Primary Completion Date: 01 Aug 2007
Study Completion Date: 01 Aug 2007
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Jaan Ruusa
Huddinge Hospital Stockholm Sweden
